Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
July 11, 2024 06:30 ET | Source: Zymeworks Inc.

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
June 17, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
June 10, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164...
May 28, 2024 06:30 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
May 02, 2024 16:05 ET | Source: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of...
April 30, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
April 11, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
April 08, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
March 28, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...